ALLK Allakos
- 1.050
- -0.020-1.87%
- 1.079
- +0.029+2.79%
Allakos News
Allakos Reports Q3 2024 Results and Research Progress
Allakos Inc. Alters Lease Agreement for Cost Savings
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
A Quick Look at Today's Ratings for Allakos(ALLK.US), With a Forecast Between $1 to $7
Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook
Piper Sandler Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Allakos(ALLK.US) With Sell Rating, Maintains Target Price $1
Allakos GAAP EPS of -$0.21 Beats by $0.03
Allakos (ALLK) Gets a Hold From TD Cowen
Express News | Allakos Inc Q3 Shr View $-0.25 -- LSEG IBES Data
Express News | Allakos Inc: Reiterates That It Expects Restructuring Activities Will Extend Cash Runway Into Mid-2026
Allakos | 10-Q: Q3 2024 Earnings Report
Allakos | 8-K: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Allakos 3Q Loss/Shr 21c >ALLK
Press Release: Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Allakos Q3 Net Income USD -18.372 Million
Express News | Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Express News | Allakos Q3 Operating Expenses USD 19.75 Million
Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?
Jasper Gains 11% on Data for Briquilimab in Urticaria
No Data